|
Abstract Objective: To explore the effect of Quetiapine combined with Sodium Valproate Sustained Release Tablets in patients with bipolar affective disorder. Method: A total of 75 patients with bipolar disorder admitted to Jiangxi Provincial Psychiatric Hospital from January 2020 to November 2022 were selected as the research subjects, and they were divided into a control group (n=37) and an observation group (n=38) using numbered singular and even forms. The control group was treated with Sodium Valproate Sustained Release Tablets, while the observation group was treated with a combination of Quetiapine and Sodium Valproate Sustained Release Tablets. The scores of the Bech-Rafaelsen mania rating scale (BRMS), neurotransmitter levels and quality of life scores were compared between the two groups. Result: Before treatment, there was no statistically significant difference in BRMS scores between the two groups (P>0.05); after 8 weeks of treatment, the BRMS scores of both groups were lower than those before treatment, and the observation group was lower than that of the control group, the differences were statistically significant (P<0.05). Before treatment, there were no statistically significant differences in the levels of 5-HT, NE and DA between the two groups (P>0.05); after 8 weeks of treatment, the levels of 5-HT, NE, and DA in both groups were lower than those before treatment, and the observation group were lower than those of the control group, the differences were statistically significant (P<0.05). Before treatment, there were no statistically significant differences in physiological function, energy, emotional function, physiological function, mental health, social function, physical pain and overall health scores between the two groups (P>0.05); after 8 weeks of treatment, the physiological function, energy, emotional function, physiological function, mental health, social function, physical pain and overall health scores of the two groups of patients were higher than those before treatment, and the observation group were higher than those of the control group, the differences were statistically significant (P<0.05). Conclusion: The combination of Quetiapine and Sodium Valproate Sustained Release Tablets can reduce the BRMS score of patients with bipolar affective disorder, regulate the expression levels of NE, 5-HT and DA, and improve the quality of life of patients.
|
|
Received: 21 April 2023
|
|
|
|
